Carbon 14 and Carbon 13 Syntheses of Velagliflozin.
animal health
carbon 13
carbon 14
diabetes
radiosynthesis
velagliflozin
Journal
Journal of labelled compounds & radiopharmaceuticals
ISSN: 1099-1344
Titre abrégé: J Labelled Comp Radiopharm
Pays: England
ID NLM: 7610510
Informations de publication
Date de publication:
11 Apr 2024
11 Apr 2024
Historique:
revised:
22
02
2024
received:
23
01
2024
accepted:
13
03
2024
medline:
12
4
2024
pubmed:
12
4
2024
entrez:
12
4
2024
Statut:
aheadofprint
Résumé
Velagliflozin is the active ingredient of the first oral liquid medication approved by the Food and Drug Administration for the treatment of diabetes in cats. This compound belongs to the known class of sodium-glucose cotransporter 2 inhibitors approved to treat diabetes in human. Here, we report the detailed synthesis of velagliflozin labeled with carbon 14 and carbon 13.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
M. A. Abdul‐Ghani and R. A. DeFronzo, “Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus,” Endocrine Practice 14 (2008): 782–790, https://doi.org/10.4158/EP.14.6.782.
J. Shubrook, B. B. Bokaie, and S. Adkins, “Empagliflozin in the Treatment of Type 2 Diabetes: Evidence to Date,” Drug Design, Development and Therapy 9 (2015): 5793–5803, https://doi.org/10.2147/DDDT.S69926.
M. Eckhardt, P. Eikelmann, F. Himmelsbach, A. Sauer, and L. Thomas, “Glucopyranosyl‐Substituted Benzonitrile Derivatives, Pharmaceutical Compositions Containing Such Compounds, Their Use and Process for Their Manufacture,” Patent WO 2007/039610 A1, filed February 14, 2007.
S. Gottlieb and J. Rand, “Managing Feline Diabetes: Current Perspectives,” Veterinary Medicine: Research and Reports 9 (2018): 33–42, https://doi.org/10.2147/VMRR.S125619.
A. J. German, “The Growing Problem of Obesity in Dogs and Cats,” The Journal of Nutrition 136, no. 7 (2006): 1940S–1946S, https://doi.org/10.1093/jn/136.7.1940S.
S. J. M. Niessen, K. Hazuchova, S. L. Powney, et al., “The Big Pet Diabetes Survey: Perceived Frequency and Triggers for Euthanasia,” Veterinary Sciences 4 (2017): 27, https://doi.org/10.3390/vetsci4020027.
C. Heiss, F. Leroux, and M. Schlosser, “Fluorine‐Flanked Congested Sites: Minimal, Though Perceptible Buttressing Effects on the Proton Mobility of Arenes,” European Journal of Organic Chemistry 2005 (2005): 5242–5247, https://doi.org/10.1002/ejoc.200500552.
F. Campagna, A. Carotti, and G. Casini, “A Convenient Synthesis of Nitriles From Primary Amides Under Mild Conditions,” Tetrahedron Letters 18 (1977): 1813–1815.
M. Hrapchak, B. Latli, X.‐J. Wang, et al., “Synthesis of Empagliflozin, a Novel and Selective Sodium‐Glucose Co‐Transporter‐2 Inhibitor, Labeled With Carbon‐14 and Carbon‐13,” Journal of Labelled Compounds and Radiopharmaceuticals 57 (2014): 687–694, https://doi.org/10.1002/jlcr.3240.
A. C. Stevens, K. Brak, W. S. Bremner, et al., “Development of a Scalable Lanthanide Halide/Quaternary Ammonium Salt System for the Nucleophilic Addition of Grignard Reagents to Carbonyl Groups and Application to the Synthesis of a Remdesivir Intermediate,” Organic Process Research and Development 26 (2022): 754–763, https://doi.org/10.1021/acs.oprd.1c00191.
D. J. Wallace and C.‐Y. Chen, “Cyclopropylboronic Acid: Synthesis and Suzuki Cross‐Coupling Reactions,” Tetrahedron Letters 43 (2002): 6987–6990.